A Prospective Cohort Study on the Prediction of Effectiveness of Sorafenib on the Basis of Angiogenesis-Related Cytokines
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Nov 2018
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 06 Nov 2018 Results published in the Journal of Gastroenterology and Hepatology
- 06 Jun 2017 Results assessing factors predicting the prognosis of advanced hepatocellular carcinoma patients treated with sorafenib, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 13 Jul 2016 Status changed from recruiting to active, no longer recruiting.